Antibody therapy against TNFα yielded promising results with diet-induced NASH in mouse and rat models showing improvement in circulating AST, ALT, steatohepatitis, and fibrosis (420–422). This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.